Interestingly, SCD1 inhibition did not impact NSC activity in symptomatic 3xTg-AD mice, nor did it impact other key AD hallmarks such as Aβ accumulation, tau aggregation, or neuronal loss. This evidence concerns the gene MAPT and Alzheimer disease.